Now showing items 1-2 of 2
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
(Lancet Neurol, 2015-08)
BACKGROUND: A systematic assessment of potential disease-modifying compounds for Parkinson's disease concluded that pioglitazone could hold promise for the treatment of patients with this disease. We assessed the effect ...
Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
(Parkinsonism & related disorders, 2017-12)
The Movement Disorders Society (MDS) published the English new Unified Parkinson's Disease Rating Scale (MDS-UPDRS) as the official benchmark scale for Parkinson's disease (PD) in 2008. We aimed to validate the Hebrew version ...